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Introduction
Synovial sarcoma (SS) is the most common soft-tissue sarcoma 
diagnosed during adolescence and young adulthood (1). SS consis-
tently bears a t(X;18) chromosomal translocation, which produces 
1 of 3 possible fusion oncogenes: SS18-SSX1, SS18-SSX2, or SS18-
SSX4 (2). No additional consistent genomic perturbations have 
been identified by profiling, suggesting that the fusion oncogene 
can drive transformation independently (3–5).
The transforming impact of an SS18-SSX fusion oncoprotein 
is profound, resulting in a germ layer cell-fate change in many 
SSs, such that, despite mesodermal origins, SS cells develop 
epithelial characteristics of endoderm and can even achieve a 
tissue morphology that includes mucinous gland formation, 
termed biphasic SS (6). This feature may have helped to keep 
the cell of origin for SS an enigma. While SS18-SSX1 and SS18-
SSX2 have each proven sufficient to initiate fully penetrant (on 
a per-animal basis) synovial sarcomagenesis when expressed in 
specific cell lineages in mice, most cell lineages cannot tolerate 
the expression of either fusion oncogene. The original mouse 
model identified the Myf5Cre lineage as permissive to synovial 
sarcomagenesis (7). This was interpreted to indicate a myoblast 
cell of origin. However, the specific Myf5 IRES-Cre–knockin 
allele used was found on other lineage-tracing experiments to 
have broader multipotency, with the lineage traced to osteo-
blasts and chondrocytes, as well as the expected myocytes (8, 9).
Among soft-tissue sarcomas, SS also has a unique relationship 
with the skeleton and osteogenesis. A close proximity to bones has 
been described as a common characteristic of SS (10, 11). SS is also 
one of very few soft-tissue sarcomas that can produce mineralized 
bone matrix within the tumor mass (12). Although this bone matrix 
is typically present in a small minority of the volumetric substance 
of an SS, an “ossifying” variant of SS, with abundant bone matrix 
dominating the tumor volume, has also been described (13–17).
In previous experiments, we combined the expression of SS18-
SSX2 with genetic stabilization of β-catenin (CTNNB1) in a localized 
tumorigenesis model induced by injection of AdCre virus or TATCre 
protein (18). We pursued these experiments because of the obser-
vation of APC-inactivating and CTNNB1-stabilizing mutations in a 
subset of human SSs, with a larger portion exhibiting deregulation 
of Wnt signaling (19–22). While the dramatic sarcomagenesis that 
resulted in the combination-genotype mice reflected this subset of 
human SSs that share overactive Wnt signaling, it also provided the 
first mouse model information relating SS to the skeleton, as these 
tumors were directly juxtaposed to and, by growth, destroyed adja-
cent bone structures. This apparent invasion suggested either that 
cells within the bone were transformed by SS18-SSX with the help 
of β-catenin stabilization, or that bones offered a welcoming micro-
environment for invasive growth of SS cells.
Differentially expressed genes in these β-catenin–stabilized 
tumors, compared with mouse SSs, which lacked genetic stabiliza-
tion of β-catenin, supported these 2 hypotheses. First, β-catenin– 
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JCI94955DS1, and Figure 1, A and B). Of the 8 SSs that were not 
juxtaposed to bone, 4 arose adjacent to the knee joint capsule 
(Supplemental Table 1 and Figure 1A), a structure similar to that 
of the periosteum in embryogenesis (29). Further, 6 of the 8 SSs 
that did not involve periosteal tissues had bone matrix produc-
tion within their substance (Supplemental Table 1). In contrast, 
a control group of 28 nonretroperitoneal, consecutive soft-tissue 
sarcomas of nonsynovial histologic type included only 8 that even 
approached proximity to the skeleton (P < 5 × 10–7, Fisher’s exact 
2-tailed analysis of these ratios; Supplemental Table 1 and Figure 
1B). A second control cohort of 28 consecutive soft-tissue sar-
comas of only pleiomorphic histology included 3 with growth in 
close proximity to the skeleton (Supplemental Table 1).
This anatomic location and proximity to bone was also reca-
pitulated in our genetically engineered mouse models of SS. When 
we conditionally activated the Rosa26-LSL-SS18-SSX2-IRESeGFP 
(hSS2) allele in the Myf5Cre lineage, we frequently detected SSs next 
to bone, with the most common locations being in the extremities 
and the rib cage (Figure 1, C–E, and Supplemental Figure 1A).
We previously observed that TATCre injections into peritibial 
tissues consistently produced tumors in hSS2 Ctnnb1ex3fl/WT mice, 
which express a floxed Ctnnb1 exon 3 (18). To test the tumor-orig-
inating capacity of other mesenchymal tissue compartments, we 
injected 8 hSS2 Ctnnb1ex3fl/WT littermate mice with 10 μl TATCre 
to delete Ctnnb1 exon 3 in cells within the tibialis anterior mus-
cle adjacent to bone, in the contralateral quadriceps muscle dis-
tant from bone, and in the subcutaneous tissue of the abdominal 
wall. By 8 weeks after injection, each of the peritibial locations 
produced a tumor (Supplemental Figure 1B); none of the subcuta-
neous-only injections produced tumors (Supplemental Figure 1C); 
stabilized tumors expressed higher levels of mesenchyme- and 
osteogenesis-related genes. This does not explicitly implicate, but 
may suggest, that these tumors derived from more bone-oriented 
cells of origin. Second, they also expressed more Opg (also known 
as Tnfrsf11b, which codes for osteoprotegerin, a secreted factor), 
which raised the possibility of microenvironmental effects of the 
bone. β-Catenin has been shown to drive the expression of OPG in 
osteoblasts (23, 24), the expression and secretion of which will shut 
down osteoclastogenesis as a RANKL dummy receptor (25, 26). 
Notably, OPG can also function as a dummy receptor for TRAIL, 
preventing extrinsic apoptosis (27). OPG expression is variable 
and generally low across reported human SS transcriptomes (28), 
and the elevated Opg expression observed in the group of β-caten-
in–stabilized mouse tumors could not be unambiguously attribut-
ed to tumor cells, as stromal cells or reactive bone tissue cells with-
in the tumor tissue might alternatively account for its expression. 
However, as a secreted protein, OPG could function in a paracrine 
fashion to provide a sarcomagenesis-enabling environment. We 
sought to study the relationship between synovial sarcomagenesis 
and the skeleton by testing each of these hypotheses more thor-
oughly through genetic experiments in the mouse models.
Results
Synovial sarcomas appear in close proximity to bone. To determine 
whether a location adjacent to bone was relatively more common 
in SSs compared with other soft-tissue sarcomas, we analyzed a 
consecutive series of 48 human SSs. We observed that 40 of these 
SSs appeared to be directly juxtaposed to bone, without inter-
vening periosteum (Supplemental Table 1; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
Figure 1. Synovial sarcomagenesis occurs in proximity to bone. (A) Representative MRIs demonstrate 
the relationship of human SSs to bone in 5 patients with tumors directly abutting the bone surface 
(black arrowheads) and 1 patient in whom the tumor did not touch the bone directly (white arrowhead), 
abutting instead the knee joint capsule. (B) Pie charts demonstrating the prevalence of neoplasms 
touching bone among human SSs (n = 48) and neoplasms near bone (within 1 centimeter) among 
non-SS human soft-tissue sarcomas (STSs) of the extremities (n = 28). (C) MRIs demonstrating SSs 
(solid white arrowheads) and adjacent bones (empty white arrowheads) in Myf5Cre hSS2 mice, as well 
as (D) H&E-stained histology images from the same, demonstrating tumor cells abutting, involving, 
or replacing periosteum (Black arrowheads indicate the periosteal surface with tumor involvement. 
Open arrowheads indicate the endosteal surface and marrow space.). Scale bars: 100 μm. (E) Pie chart 
demonstrating the prevalence of tumor cells touching the bone surface in random sections of tumors 
from 8 mice (n = 33 tumors).
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mice lack the developmental side effects of Myf5Cre lineage trans-
formation. These locally induced tumors developed more slowly 
in the mice lacking OPG (Figure 2D).
Embryonic Myf5Cre-expressing cells, but not postnatal myoblasts, 
can give rise to SS. To test whether postnatal myoblasts expressing 
Myf5Cre could give rise to SSs, an allele with SS18-SSX2 under the 
control of the TetO promoter, and separated from it by a floxed 
stop cassette, was targeted to a noncoding region in the RNAPolII 
locus (this allele was termed hSS2T) (Figure 3A). Fourteen days 
postcoitum, embryonic fibroblasts, which were heterozygous for 
both the hSS2T allele and an allele that places the reverse tet trans-
activator (rtTA) in the Rosa26 locus behind a floxed stop (30), were 
harvested and recombined in vitro by the application of TATCre or 
vehicle and exposed to either doxycycline or saline control. These 
cells demonstrated a mild GFP signal from recombination of the 
rtTA allele, but stronger GFP fluorescence from the activation of 
the hSS2T allele after TATCre application and in the presence of 
doxycycline (Figure 3B).
Next, we bred mice to be triple-heterozygous for Myf5Cre, the 
conditional rtTA allele, and the hSS2T allele. Cohorts of these mice 
were provided drinking water with 0, 1, 2, or 6 mg/ml doxycycline 
and 5% sucrose continuously after weaning (3 weeks of age). We 
maintained these mice for over a year and found that no tumors had 
developed (Figure 3C; n > 25 per dose group). For a second cohort 
of mice, the parents were bred with continuous doxycycline expo-
sure at the same doses (but therefore beginning from conception 
for the experimental mice). No pups were born to the breeding pairs 
exposed to the 6-mg/ml dose of doxycycline. Only 1 litter of 5 pups 
was born to 1 of the pairs exposed to 2 mg/ml doxycycline. Each of 
these mice formed tumors over the course of 1 year of continuous 
and 5 of the 8 quadriceps muscle injections produced tumors, 3 of 
which developed adjacent to the posterior femur (Supplemental 
Figure 1, D–F). These data cannot prove that cells with osteogen-
ic differentiation potential are the cells of origin for these tumors, 
but they suggest that synovial sarcomagenesis has an unusual pre-
dilection for growing near the skeleton.
Osteoprotegerin can enable synovial sarcomagenesis, but is not 
necessary for it. To test the potential contribution of paracrine OPG 
to synovial sarcomagenesis, we locally administered recombi-
nant mouse OPG (rmOPG) every other day (or vehicle control) to 
4-week-old hSS2 mice following TATCre injection into the tibia-
lis anterior muscle. Compared with the vehicle control injections, 
rmOPG significantly enhanced the survival of GFP-fluorescent, 
SS18-SSX2–expressing cells 2 weeks after TATCre injection (Fig-
ure 2, A–C), suggesting a role for paracrine OPG in enabling syno-
vial sarcomagenesis at an early stage.
To test the impact of genetically removing Opg gene function, 
we bred mice to be WT, heterozygous, or homozygous for a spon-
taneous loss-of-function mutant allele of Opg as well as heterozy-
gous for both Myf5Cre and hSS2. These were difficult experiments 
to perform, given that Myf5Cre hSS2 mice are already develop-
mentally challenged, with severe kyphosis and weight loss that 
accompanies, but are independent of, tumorigenesis and likely 
results from Myf5 lineage loss (5, 7, 8). The added developmen-
tal side effects of lost OPG function led to the early death of the 
combination mutant mice as a result of morbidity that was also not 
tumor related (Supplemental Figure 2).
We repeated the experiment in mice via localized induction 
of SS by TATCre injection into homozygous hSS2 mice that were 
either homozygously WT or homozygously mutant for Opg. These 
Figure 2. Osteoprotegerin enhances early synovial sarcomagenesis but is not critical to it. (A) Gross light and GFP fluorescence micrographs from hSS2 
heterozygous mice that developed appreciably transformed tissue (white arrowheads) by 6 weeks of age, after injection into the anterior compartment of 
the leg at 4 weeks of age of TATCre, followed by vehicle or rmOPG-Fc, every 48 hours until harvest. Scale bars: 1 mm. (B) Plot of the 2D area of persistent 
GFP fluorescence following the vehicle control or rmOPG-Fc injections  (bars indicate the mean; n = at least 6 per group; P = 0.0066, by 2-tailed Student’s 
t test). (C) H&E histology photomicrograph representative of surviving GFP+ tissue in either group. Scale bar: 100 μm. (D) Growth curves of tumors in hSS2 
homozygous mice with noted Opg genotypes, injected with TATCre at 4 weeks of age. Data represent the mean ± SEM. P = 0.04, by ANOVA; P < 0.04, by 
2-tailed Student’s t test for comparisons of mice aged ≥244 days.
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tracing after embryonic expression of Myf5Cre suggested that the 
lineage includes some degree of osteochondroprogenitor differ-
entiation capacity (8). To evaluate osteochondroprogenitors for 
their SS-originating potential, we conditionally activated the hSS2 
allele at various stages of osteoblast differentiation (Figure 4A). 
SS18-SSX2 expression in OcCre+ cells (mature osteoblasts) result-
ed in no offspring surviving beyond the first day of life (Figure 4A). 
Likewise, few pups survived to genotyping at age 2 weeks and even 
fewer beyond weaning at age 3 weeks among the Col1a1Cre+ hSS2+ 
double-heterozygotes (preosteoblasts, Figure 4A) (31). The 3 pups 
that survived had densely ossified skeletons, but no detectable 
tumors in the soft tissue or the bones (Figure 4, A–C). These results 
highlight the developmental toxicity of the fusion oncoprotein in 
osteoblasts and preosteoblasts during embryonic development, as 
dense expression of SS18-SSX2 across these entire lineages drives 
developmental failure without tumorigenesis. This also fit with 
previous data demonstrating that Prx1Cre was lethal as an embry-
onic initiator of the hSS2 allele (7).
To avoid embryonic/developmental toxicity of SS18-SSX 
expression across entire lineages, we turned our attention to tamox-
ifen-inducible Cre recombinase systems. Postnatal restriction of 
doxycycline exposure (Figure 3C). Of the 25 mice born under condi-
tions of 1 mg/ml embryonic exposure, 2 formed tumors during the 
year of monitoring (Figure 3, C–F). These data suggest that the post-
natal Myf5Cre lineage does not retain the SS-originating potential 
that it demonstrates embryonically and that myoblasts specifically 
may not harbor strong SS-originating potential.
To test the SS-originating potential of muscle progenitors 1 
step earlier along the postnatal myogenic differentiation pathway, 
we induced SS18-SSX2 expression in the Pax7 lineage by tamoxi-
fen dosing on day 5 or 8 of life in 2 cohorts of Pax7CreERT2+ hSS2+ 
mice. None of these mice developed tumors over the course of 1 
year of monitoring (Figure 3C). Of note, while the myogenic pre-
cursors defined by the postnatal Myf5Cre or Pax7CreERT2 lineages 
showed no significant origination potential for SS from expres-
sion of SS18-SSX2, prior data from localized, lineage-nonspecific 
induction of hSS1 or hSS2 expression had already demonstrated 
that some postnatal cells in both periosteal and muscle compart-
ments retained origination potential (5, 18).
SS18-SSX2 expression is tolerated by differentiating osteoblast 
precursors and transforms the more primitive of these. The nonmyo-
genic fraction of differentiated cell types marked from lineage 
Figure 3. Synovial sarcomagenesis induced by Myf5Cre is restricted to its embryonic, multipotent lineage, not  post-
natal muscle progenitors. (A) Schematic of inducible alleles in mice, which depend on Cre-mediated recombination of 
the rtTA and the TetO promoter–controlled SS18-SSX2 allele (hSS2T), plus the presence of doxycycline for expression of 
the fusion oncogene. (B) Fluorescence photomicrographs showing some GFP from the recombination of rtTA and more 
GFP from the activation of hSS2T in embryonic fibroblasts in culture. Scale bars: 100uM. (C) Schematic and Kaplan-Mei-
er plots of the absence of tumorigenesis in 5 groups with noted genotypes and doxycycline or postnatal induction with 
tamoxifen as well as rates of tumorigenesis in 2 groups with embryonic induction of SS18-SSX2 expression (n = 25 per 
group; log-rank test Z score = 4.48 aænd P < 0.001, comparing 2 mg and 1 mg dosing). (D) Gross image, (E) GFP fluores-
cence image, and (F) H&E histology photomicrographs of a limb tumor that developed in a 6-month-old Myf5Cre hSS2T 
mouse after embryonic initiation of doxycycline (1 mg/ml). Open arrowheads indicate biphasic histologic features of 
mucinous gland formation. Scale bar: 100 μm.
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disorganized matrix and also evidence of continued expression 
of the fusion by EGFP (Figure 5, E–G). These data suggested that, 
among preosteoblasts, a subpopulation of cells tolerated SS18-
SSX2 expression without malignant transformation. Extensive 
prior work had not identified any such cells that expressed the 
fusion but did not transform. Even cells in the Myf5Cre lineage 
were either destroyed or gave rise to tumors, in that we found no 
residual Cre-recombined, hSS2-expressing cells outside of the 
tumors in these mice.
The tumors that formed in the lower lips of Prx1CreERT2 hSS2 
mice showed strong GFP fluorescence, indicative of fusion gene 
expression (Figure 6, A–C). Histologic sections showed spin-
dle-shaped cells typical of SS, with characteristic immunohisto-
chemical profiles (Figure 6, D–F). Cross-sectional analysis of the 
jaw revealed the close proximity of each tumor to the bone (Figure 
6G). To verify the localized lineage restriction of Cre expression in 
the jaw/lip area, we analyzed Prx1CreERT2 Rosa26LacZ mice at 3 weeks 
of age, following tamoxifen administration at 2 weeks of age. The 
expected periosteal mesenchymal progenitor cells of the mandible 
osterix (Osx) to preosteoblasts offered the opportunity to determine 
whether hSS2 could transform preosteoblasts without embryonic 
consequences (32, 33). After administering tamoxifen to 4-week-
old OsxCreERT hSS2 mice, the mice were followed for 12 months and 
showed no sarcoma formation or any apparent skeletal phenotype 
(Figure 4, A and D). To induce SS18-SSX2 expression in earlier 
osteochondroprogenitors, we administered tamoxifen to 2-week-
old Prx1CreERT2 hSS2 mice. Sarcomas developed in 6 of 7 mice, all on 
the lower lip, adjacent to the mandible (Figure 4, A and E).
Late OcCre hSS2 embryos, harvested prior to their perinatal 
demise, had dense bone formation and the apparent absence of 
hematopoietic progenitors in the marrow space (Figure 5, A and 
B). This niche-ablating effect has been described for the OcCre 
lineage in other conditional gene manipulations (24). Important-
ly, the spindled, marrow-replacing cells showed evidence of the 
recombined Rosa26 locus and expression of the fusion by the 
detected presence of its surrogate marker, EGFP (Figure 5, C and 
D). The few surviving Cola1Cre hSS2 mice also had shortened, 
but very dense, bones compared with those of the controls, with 
Figure 4. Impact in periosteal cells following activation of SS18-SSX2 expression. (A) Schematic of Cre drivers and survival of mice, with or without 
tumorigenesis following activation of hSS2 at various stages of osteoblast differentiation. (B) Posteroanterior radiographs of control and (C) Col1a1Cre 
hSS2 mice at 2 months of age, showing shortened, osteopetrotric bones in the latter. (D) Radiographs of OsxCreERT hSS2 mice at 12 months of age after 
tamoxifen administration at 4 weeks of age, showing no discernible skeletal phenotype. (E) Representative radiograph of a 9-month-old Prx1CreERT2 hSS2 
mouse that received tamoxifen at age 2 weeks of age and then developed the characteristic perimandibular SS (blue arrowhead).
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were the sole lineage marked in these tracing experiments (Figure 
6G). Notably, the adjacent enamel epithelium of the tooth has been 
shown to express and secrete high levels of OPG (34).
Stabilized β-catenin and SS18-SSX expression enhance sar-
comagenesis in mesenchymal progenitors. Given the observed 
enhancement of tumorigenesis when stabilization of β-catenin 
accompanied localized activation of hSS2 (18), we combined the 
Ctnnb1ex3fl and hSS2 alleles under the control of Prx1CreERT2. Injec-
tion of tamoxifen into 2-week-old mice led to dramatic tumorigen-
esis, with the entire periosteal surface of the forelimb skeleton (the 
primary lineage of postnatal Prx1-expressing cells) erupting into 
massive tumors, all before the age of 3 months (Figure 7, A–I). Lit-
termate control mice, lacking either hSS2 expression or β-catenin 
stabilization, produced no tumors within a similar time frame (Fig-
ure 7A). The Prx1CreERT2 hSS2 Ctnnb1ex3fl tumors had classic SS his-
tologic features and immunohistochemical profiles (Figure 7, J–L).
Prx1CreERT2 Ctnnb1ex3fl littermates that lacked the hSS2 allele 
showed the impact of β-catenin stabilization on the Prx1CreERT2 
lineage. These mice had a consistent phenotype at 1 year of age. 
Radiographs showed that the bones of the clavicle and forelimb 
had increased mineral density and thickened trabecular struc-
ture, respectively (Figure 8, A and B). Histopathology revealed an 
extensively thickened layer of periosteal undifferentiated mes-
enchyme in the forearm (Figure 8, C and D) and areas of both 
cartilaginous and osseous differentiation, as shown by Masson’s 
trichrome staining (Figure 8E). Each mouse of this genotype had 
also developed a bland, fibrous, tumor-like thickening of the man-
dible (Figure 8, F and G). The fibrous jaw masses had a microscop-
ic appearance resembling the clinical entity termed an ossifying 
fibroma, with encapsulated islands of osteoid and cartilaginous 
matrix formation, each identified by Masson’s trichrome staining 
(Figure 8, H and I). The matrix islands contained no embedded 
osteocytes. Osteoblasts blocked from terminal differentiation 
would be excluded from the matrix they produce, as osteocyte 
embedding is linked to cell-cycle exit and terminal differentiation 
(35). The production of both osteoid and chondroid matrix con-
Figure 5. Pre- and perinatal osteoblasts tolerate SS18-SSX2 expression, but render dense and disorganized skeletal phenotypes. (A) H&E histology 
photomicrographs of tibiae from control and OcCre hSS2 embryos harvested 18.5 days postcoitum show dense, woven bone replacing the medullary canal 
in the latter. (B) Higher-power photomicrographs from the same groups show the replacement of hematopoietic progenitor cells with spindle-shaped 
osteoblasts in the latter. Photomicrographs of anti-EGFP IHC in a Myf5Cre hSS2 tumor (C, positive control) and bone sections from (D) an OcCre hSS2 
embryo and (E) the Col1a1Cre hSS2 mouse that survived to 6 months, showing fusion expression in osteoblasts in the latter 2. (F) Micro-CT axial, coronal, 
and sagittal images of the tibia from a control mouse and the only surviving Col1a1Cre hSS2 mouse at 6 months of age, showing short, dense, and poorly 
remodeled bones in the latter. (G) H&E histology photomicrographs of cortical bone from the same mice as in F reveal contrasting lamellar control bone in 
the former and disorganized ossification patterns in the latter. Scale bars (A, B, G) and panel widths: 100 μm (C–F).
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firmed the extended maintenance of an incompletely differenti-
ated state, as along the course of mesenchymal differentiation, 
cells retaining both osteoblastic and chondrogenic characteristics 
precede those committed to either lineage (36).
β-Catenin stabilization enables SS18-SSX2–mediated transfor-
mation of preosteoblasts. Given the dramatic enhancement of sar-
comagenesis from the addition of β-catenin stabilization to hSS2 
activation in mesenchymal progenitors and the observation that 
this effectively blocked or slightly reversed the differentiation 
state of the lineage, we next tested whether such a shift along the 
differentiation pathway of osteoblasts could be effected in the 
OsxCreERT lineage by β-catenin stabilization. Mice were bred to 
bear heterozygosity for Ctnnb1ex3fl, hSS2, and OsxCreERT and inject-
ed with tamoxifen at 2 or 4 weeks of age. Triple-heterozygous 
mice also formed tumors that arose from much of the surface of 
the appendicular skeleton, with complete penetrance, and each 
tumor had classic SS histology and immunohistochemical pro-
files (Figure 9, A–I). Control mice, with activation of either hSS2 or 
Ctnnb1ex3fl alone in postnatal preosteoblasts, developed no tumors 
by 12 months of age (Figure 9A), but the latter allele revealed the 
developmental impact of β-catenin stabilization. Radiographic 
and histologic examination identified a fibro-osseous jaw mass in 
only 1 of 7 mice of this genotype (Supplemental Figure 3A). Tri-
chrome staining revealed that the osteoid matrix islands within 
the fibroblastic proliferation in this mass contained no chondroid 
matrix (Supplemental Figure 3B). This lack of chondroid matrix 
correlated with the slightly later stage of osteoblast-directed dif-
ferentiation at which β-catenin was stabilized in these mice, rel-
ative to the mice with β-catenin stabilization in the Prx1CreERT2 
lineage (compare with Figure 8I). OsxCreERT Ctnnb1ex3fl mice also 
showed an increased, osteopetrosis-like density in the mid-por-
tions of the appendicular long bones, with or without the addition 
of hSS2 (Figure 9, B–E). The increased density in the long bones 
matched the trabecular morphology and position of the primary 
spongiosa that would have been present in these mice at the age 
of 4 weeks, when tamoxifen was administered (Figure 9, J and 
K), suggesting that the blockade to osteoclastogenesis was nearly 
complete in these portions of the bone. Bony trabeculae in these 
areas were thick and dense, as reflected in the area measurements 
from photomicrographs (Figure 9L), consistent with absent osteo-
clast activity. Tartrate-resistant acid phosphatase (TRAP) staining 
identified significantly fewer osteoclasts in these areas compared 
with that seen in the metaphyses of normal-bone, age-matched 
controls (Figure 9M).
Discussion
These data challenged our earlier interpretation that the SS-orig-
inating potential of the Myf5Cre lineage indicated a myoblast. We 
must now conclude that postnatal myoblasts and their postnatal 
myogenic precursors are unlikely candidates for the cell of origin 
implicated by the Myf5Cre lineage. Further, exogenous OPG had a 
paracrine impact, enabling early growth of SS18-SSX2–transform-
ing cells, and genetic silencing of Opg slowed synovial sarcoma-
genesis. Finally, early mesenchymal progenitor cells with strong 
Figure 6. Expression of SS18-SSX2 in postnatal Prx1CreERT2 lineage induces synovial sarcomagenesis. (A) Pre- and (B) post-dissection gross images 
as well as (C) a GFP fluorescence image demonstrating a representative submandibular tumor that occurred on 6 of 7 of the Prx1CreERT2 hSS2 mice. (D) 
Representative H&E histology photomicrograph shows typical features of a monophasic SS. Classic SS immunohistochemical staining demonstrates 
(E) cytoplasmic BCL2 and (F) nuclear TLE1. (G) Photomicrograph of X-gal staining of the mandible from a Prx1CreERT2 LacZ mouse showing the periosteal 
lineage (blue, left) as well as H&E staining of an SS tumor apparently arising from the same tissue layer in a Prx1CreERT2 hSS2 mouse (right), with adjacent 
enamel epithelium, a strong source of OPG production. Scale bars: 50 μm.
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in osteochondroprogenitors and by the additional enhancement 
of synovial sarcomagenesis from the paracrine secretion of OPG, 
which is highly expressed in bones. These observations also suggest 
an explanation of the typical age distribution for SS in adolescents 
and young adults. Both mesenchymal progenitor cell populations 
and OPG secretion diminish as humans age past young adulthood.
osteoblast differentiation potential proved capable of tolerating 
SS18-SSX2 expression and even transformation from expression 
of SS18-SSX2, especially with the added boost of β-catenin stabi-
lization. Thus, the observation that human SS often arises in close 
proximity to bones and often has areas of osteoid matrix production 
within the tumor can be explained by the transforming potential 
Figure 7. Stabilization of β-catenin promotes SS18-SSX2–driven transformation of mesenchymal progenitors. (A) Kaplan-Meier plot of the fraction 
without tumor among Prx1CreERT2 mice bearing hSS2, Ctnnb1ex3fl, or both conditional alleles (n = 7 for each; log rank test Z score = 3.83 and P < 0.001). (B) 
Posteroanterior radiographs of a control mouse and (C) a Prx1CreERT2 hSS2 Ctnnb1ex3fl mouse at 10 weeks of age, as well as posteroanterior photographs of 
the same (D and E, respectively), showing bulky tumorigenesis in periscapular regions (solid arrowheads) and forearms (open arrowheads) of the combi-
nation genotype mouse. (F) Gross dissection photograph and (G) GFP fluorescence image of the latter mouse. (H) H&E histology photomicrographs from 
sagittal sections through the elbow in a control mouse and (I) a combination genotype mouse, showing tumorigenesis from every bone surface along the 
ulna and radius (open arrowhead). (J) Higher-power H&E histology photomicrograph from a tumor arising along the periosteal surface of a Prx1CreERT2 hSS2 
Ctnnb1ex3fl mouse at 10 weeks of age, showing classic SS features of staghorn-style hemangiopericytomatous vessels (solid arrowhead) and pseudoglan-
dular structures (open arrowhead), along with (K) classic immunohistochemical staining images for cytoplasmic BCL2 and (L) nuclear TLE1. Scale bars: 100 
μm (H–J); panel widths: 100 μm (K and L).
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Finally, mouse genetic experiments can test the necessity of 
specific genes for transformation by their removal from otherwise 
efficient models of tumorigenesis. Such negative genetic experi-
ments may be performed in the transforming cells or in the sur-
rounding cells. By using a nonconditional germline mutant allele 
for Opg loss of function, we did not distinguish between these two. 
Therefore, both tumor cell–autonomous effects of lost OPG and 
lost paracrine OPG from host tissues, such as bone, were com-
bined in these experiments. Because few human SSs express OPG 
directly, we assumed that we were testing the paracrine impact 
from nontumor cells. Nonetheless, we cannot exclude the impact 
of cell-autonomous effects of lost OPG, because the tumor cells 
also lacked functional Opg.
SS has been termed a stem cell malignancy (39). The stem-like 
state of SS cells may not derive entirely from a stem-like cell of origin, 
as even preosteoblasts gave rise to SSs with the appropriate induce-
ment. Some level of differentiation must be reversible through the 
transformation process. If a periosteal cell requires no “second hit” 
more drastic than stabilization of β-catenin to render synovial sar-
comagenesis efficient, it may achieve that stabilization in a variety 
of ways. APC-inactivating and β-catenin–stabilizing mutations have 
been described in approximately 20% of human SSs (19–22), but 
many other genetic, epigenetic, paracrine, and microenvironmen-
tal forces converge upon β-catenin stabilization. These alternate 
mechanisms of β-catenin stabilization are likely at work in a large 
portion of the poor-prognosis SSs with aberrant staining patterns for 
β-catenin. They may also provide alternate means of enabling SS18-
SSX–driven oncogenesis in cells as differentiated as preosteoblasts.
Mouse genetics experiments can provide proof of the sufficiency 
of specific combinations of cell lineages and transforming events for 
tumorigenesis but will never prove which cells truly give rise to simi-
lar tumor types in humans. Because the very character of each exper-
iment results in tumorigenesis or no tumorigenesis, any untested 
variable may be the key between the 2 potential results. For example, 
elegant work by others has recently demonstrated that the sarcoma-
genesis-originating potential of satellite cells in particular depends 
on their activation in response to injury (37, 38). Our experiments did 
not address the application of this principle to synovial sarcomagene-
sis, but future work should. Injury response or β-catenin stabilization 
may be the key missing ingredient in synovial sarcomagenesis from 
postnatal muscle precursors, just as β-catenin stabilization appears 
to enable some more-differentiated periosteal cells of origin.
Mouse genetic experiments can also offer information 
regarding comparative efficiency, which, in the case of both the 
Prx1 and Osx postnatal lineages, was the strongest seen in any 
model we have developed thus far. The addition of β-catenin 
stabilization to each of these originating lineages enabled both 
initiation (apparent by the additional numbers of tumors form-
ing in each model) and progression (apparent by the rapid devel-
opment of these tumors). Notwithstanding, these data cannot 
make a compelling argument that periosteal osteochondropro-
genitors are the cells of origin for human SS, as some human SSs 
arise in anatomic locations distant from the skeleton (such as 
primary pulmonary SSs); the efficiency data can only suggest 
that conditions  may be suitable for such cells to potentially 
serve as a frequent cell of origin for SS case.
Figure 8. β-Catenin stabilization in bone progenitors promotes proliferation and blocks differentiation. (A) Posteroanterior radiographs of a control 
mouse and (B) a Prx1CreERT2 Ctnnb1ex3fl mouse at 12 months of age show thickening of the clavicle (white arrowhead) and periosteal thickening (open black 
arrowheads) in the latter. (C) H&E histology photomicrographs of the ulnar cortex from a control mouse and (D) a Prx1CreERT2 Ctnnb1ex3fl mouse show the 
thickened periosteal mesenchyme layer, which contained (E) both osseous (red) and cartilaginous (blue) matrix production on Masson’s trichrome staining. 
Open arrowhead indicates the thickened periosteum. (F and G) Lateral projection radiographs of a control mouse and a Prx1CreERT2 Ctnnb1ex3fl mouse show 
the same forearm periosteal reaction (open arrowhead) as well as a bone matrix–forming mass arising from the jaw (black arrowhead) in the latter. (H) 
H&E-stained photomicrograph of one of these jaw masses shows a bland fibroblastic proliferation containing (I) islands of osseous (red) and cartilaginous 
(blue) matrix on the Masson’s trichrome–stained image. Scale bars: 100 μm.
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For all comparison cohort experiments, littermate controls were 
used to mitigate any impact from the mixed SvJ and Bl/6 background. 
TATCre injections were 10 μl of a 42-μM concentration. rmOPG-Fc 
(R&D Systems) dissolved in saline vehicle was injected (2.5 mg/kg) 
into each anterior leg compartment every 48 hours. Doxycycline was 
mixed at the noted concentrations into 5% sucrose drinking water that 
was protected from light and changed every 72 hours. Caliper measure-
ments of tumors were performed weekly in the proximal-to-distal and 
medial-to-lateral dimensions of the palpable hind limb tumors, and 
then the volumes were calculated by multiplying the longer dimension 
by the square of the shorter dimension, divided by 2.
Clinical. Consecutive SS patients were identified from a diagnos-
tic search through pathology archives and included only if the molecu-
lar diagnosis was confirmed and if an MRI of the primary tumor prior 
to surgery was available. Soft-tissue sarcoma samples and MRIs were 
consecutively collected from control patients and confirmed not to 
have synovial histopathologic features.
Imaging. Radiographs of sedated mice were obtained using a Kodak 
Carestream 4000 Pro Fx imaging machine (Carestream Health Inc.). 
Methods
Mice. The Rosa26hSS2 and Myf5Cre mouse strains were previously gen-
erated in the laboratory (7); the Ctnnb1ex3fl mouse strain was shared by 
Makoto Mark Taketo (Kyoto University, Kyoto, Japan) (40); Rosa26rtTA 
mice were purchased from The Jackson Laboratory (30); Opg-mutant 
mice were purchased from The Jackson Laboratory (41); the Prx1CreERT2 
mouse strain was shared by Malcolm Logan (King’s College in London, 
London, United Kingdom) (42); the OsxCreERT mouse strain was shared 
by Henry Kronenberg (Massachusetts General Hospital, Boston, Massa-
chusetts, USA) (43); Col1a1Cre mice were purchased from The Jackson 
Laboratory (31); and the OcCre mouse strain was shared by Thomas Cle-
mens (Johns Hopkins University, Baltimore, Maryland, USA) (44).
The hSS2T allele was targeted to the 3′-UTR region of the RNAPolII 
locus in R1 embryonic stem (ES) cells. G418-resistant clones were 
screened by long-range PCR and Southern blotting to confirm full-length 
integration. One successfully targeted clone was injected into blasto-
cysts. High-percentage chimeric male mice were bred, and F1-genera-
tion pups were genotyped again by long-range PCR and Southern blot-
ting and then by standard Rosa26 PCR genotyping thereafter.
Figure 9. β-Catenin stabilization enables synovial sarcomagenesis from preosteoblasts. (A) Kaplan-Meier plot of tumorigenesis among OsxCreERT mice bear-
ing hSS2, Ctnnb1ex3fl, or both and that received tamoxifen at 2 weeks of age (solid line; n = 7; log rank test vs. control Z score = 3.15 and P =0.0016) or 4 weeks of 
age (dotted line; n = 7; Z score = 3.85 and P < 0.001). (B and C) Posteroanterior radiographs of OsxCreERT Ctnnb1ex3fl mice at 12 months of age, showing increased 
skeletal density, especially in apparently residual primary spongiosal regions, now in the metadiaphysis (open arrowhead). (D and E) OsxCreERT hSS2 Ctnnb1ex3fl 
mice at age 12 weeks of age with the same findings (open arrowhead) plus periosteal reactive bone and soft-tissue shadows (solid black arrowheads). (F) Gross 
dissection and (G) GFP fluorescence images show multiple periscapular tumors (solid black arrowheads) in a 12-week-old OsxCreERT hSS2 Ctnnb1ex3fl mouse. (H) 
Scapular H&E photomicrographs from a control mouse and (I) a OsxCreERT hSS2 Ctnnb1ex3fl mouse, the latter showing tumors (solid black arrowheads). (J) Photomi-
crographs of H&E staining of femur sagittal sections from a control mouse and (K) a OsxCreERT Ctnnb1ex3fl mouse, the latter showing dense, unremodeled primary 
spongiosa (open arrowhead). (L) Graph of fractions of trabecular bone area in metaphyseal femora from 12-week-old OsxCreERT Ctnnb1ex3fl/WT or Ctnnb1WT/WT mice 
(bars depict the mean; n = 7 femora; P < 0.0001, by 2-tailed Student’s t test). (M) Graph of TRAP+ osteoclasts (OCs) per high-power field (HPF) (bars depict the 
mean; n = 4 femora per group and ≥5 areas counted per femur; P < 0.0001, by 2-tailed Student’s t test). Scale bars: 100 um.
Downloaded from http://www.jci.org on January 21, 2018.   https://doi.org/10.1172/JCI94955
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 1 7jci.org   Volume 128   Number 1   January 2018
were performed using a 2-tailed Student’s t test, with a P value of less 
than 0.05 considered significant.
Study approval. All mouse experiments were conducted with the 
approval of the IACUC of the University of Utah and in accordance 
with international legal and ethical standards. Clinical analyses were 
performed with approval from the IRB of the University of Utah and 
in accordance with legal and ethical standards. As only extant records 
were reviewed, the requirement for consent was waived by the IRB.
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Gross light and fluorescence images were obtained postmortem with 
a Leica AF6000 dissecting microscope (Leica Microsystems). Light 
microscopy was performed and images digitally photomicrographed 
using an Olympus BX43 microscope and a DP26 camera (Olympus 
America). CT images were acquired using an Inveon Trimodality PET/
SPECT/CT Scanner (Siemens Preclinical Solutions). CT images consist-
ing of 360 degrees and 540 projections were acquired first. The exposure 
time was 1.5 seconds, with detector settings at 80 kVp and 250 μA. Data 
were reconstructed onto a 1,056 × 1,056 × 1,728 image matrix using the 
COBRA software package (Exxim Computing Corp.). Consequently, the 
effective image voxel size was 47.1 μm (isotropic). Reconstructed images 
were analyzed and visualized using 3DSlicer, version 4.6.2 (45).
Trabecular area and GFP area measurements were performed 
using Photoshop (Adobe) to select and mark color-defined areas, and 
then ImageJ (NIH) to measure threshold areas.
Histology. Tissues were harvested postmortem, fixed in 4% para-
formaldehyde overnight, decalcified (if including bone) in 14% eth-
ylenediaminetetracetic acid at pH 7.4 for 2 weeks at 4°C, and embed-
ded in paraffin following serial dehydration in ethanol, or embedded 
and frozen in OCT (Sakura Finetek) following serial glucose gradient 
dehydration for X-gal staining. In addition to standard H&E staining, 
IHC was also performed for mouse TLE1 (1:50 dilution; clone M101; 
Santa Cruz Biotechnology); BCL2 (1:500 dilution; clone mw-26; Santa 
Cruz Biotechnology); and EGFP (1:500 dilution; catalog OSE00003G; 
Thermo Fisher Scientific) using an IgG-HRP goat anti-rabbit secondary 
antibody (1:5,000 dilution; sc-2004; Santa Cruz Biotechnology) and 
counterstained with hematoxylin. TRAP cytochemical staining was 
performed by incubating slides at 37°C for 1 hour in phosphate-buffered 
4% TRAP substrate solution (ARUP) and 0.016% pararosaniline and 
sodium nitrite, followed by hematoxylin counterstaining.
Statistics. The statistical analyses pertinent to each experiment are 
noted in the figure legends, including sample sizes. Statistical analyses 
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